Seeking Alpha

Oncomed comes off its quiet period with a few upbeat initiations

  • Recent IPO OncoMed Pharmaceuticals (OMED-2%) slips today despite a few upbeat initiations by Wall Street firms:
  • Jefferies starts the shares with a Buy and a $27 price target, saying OMED is a leader in the science behind cancer stem cells, which are thought to drive progression and metastases, and has generated five clinical stage candidates in Phase 1 trials using its platform, which has created multiple opportunities for success in major solid tumors and hematologic malignancies.
  • Jefferies acted as lead bookrunner in the IPO In July.
  • Leerink Swann and BMO Capital also ramp up coverage with an Outperform, and Piper Jaffray with an Overweight.
Comments (1)
  • rambler1
    , contributor
    Comments (395) | Send Message
    After the IPO over hype now its another show me biotech.
    12 Aug 2013, 03:45 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: